---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-105533"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2024-10-03T23:59:59+00:00"
generated_at: "2026-05-30T21:04:09.006618+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Novavax clarifies it has not updated FY2024 guidance after analyst report

## Summary
- Analyst report published Oct 1, 2024 cited management discussions on US COVID-19 vaccine market.
- Novavax has not updated or reaffirmed its full year 2024 guidance issued August 8, 2024.
- Company expects US COVID-19 vaccination market for 2024-2025 season to be similar to last year.
- No change to previously issued FY2024 guidance; no new financial information provided.

## SEC filing metadata
- accession: 0001104659-24-105533
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2024-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465924105533/0001104659-24-105533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465924105533/tm2425496d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-105533
- JSON: https://secwatch.observer/filing/0001104659-24-105533.json
- Plain text: https://secwatch.observer/filing/0001104659-24-105533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.